KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Current Assets: 2009-2024

Historic Current Assets for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Dec 2024 value amounting to $135.1 million.

  • Rigel Pharmaceuticals' Current Assets rose 101.87% to $214.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $214.9 million, marking a year-over-year increase of 101.87%. This contributed to the annual value of $135.1 million for FY2024, which is 36.10% up from last year.
  • Latest data reveals that Rigel Pharmaceuticals reported Current Assets of $135.1 million as of FY2024, which was up 36.10% from $99.3 million recorded in FY2023.
  • Rigel Pharmaceuticals' Current Assets' 5-year high stood at $154.5 million during FY2021, with a 5-year trough of $89.0 million in FY2020.
  • Over the past 3 years, Rigel Pharmaceuticals' median Current Assets value was $115.9 million (recorded in 2022), while the average stood at $116.8 million.
  • In the last 5 years, Rigel Pharmaceuticals' Current Assets decreased by 25.23% in 2020 and then skyrocketed by 73.59% in 2021.
  • Yearly analysis of 5 years shows Rigel Pharmaceuticals' Current Assets stood at $89.0 million in 2020, then spiked by 73.59% to $154.5 million in 2021, then decreased by 24.97% to $115.9 million in 2022, then declined by 14.35% to $99.3 million in 2023, then surged by 36.10% to $135.1 million in 2024.